Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.47 |
| ▸ | MIF | P14174 | 3/20 | 0.47 |
| ▸ | CD74 | P04233 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667227 | 0.83 | MEN1 (0.61) | MEN1KMT2AP2RX4 | |
| SCHEMBL31667148 | 0.79 | POLB (0.54) | POLBMEN1KMT2ATNIKMIF | |
| SCHEMBL31667732 | 0.79 | POLB (0.54) | POLBMEN1KMT2ATNIKMIF | |
| SCHEMBL31667662 | 0.78 | POLB (0.51) | POLBMEN1KMT2ATNIKMIF | |
| SCHEMBL31667438 | 0.75 | MIF (0.71) | POLBMEN1KMT2AMIFCD74 | |
| SCHEMBL18805706 | 0.74 | MIF (0.62) | POLBMEN1KMT2ATNIKMIF | |
| SCHEMBL31667699 | 0.73 | POLB (0.48) | POLBMEN1KMT2ATNIKMIF | |
| SCHEMBL9645137 | 0.73 | ALOX5 (0.52) | — | |
| SCHEMBL34475640 | 0.72 | POLB (0.52) | POLBMEN1KMT2ATNIKMIF | |
| SCHEMBL16131495 | 0.71 | MEN1 (0.56) | POLBMEN1KMT2AP2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | POLB 1690/4885MEN1 2008/4885KMT2A 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.